Preprint
Article

Racial Impact on Inpatient Stroke Quality of Care in Two Community Hospitals

Altmetrics

Downloads

73

Views

47

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

31 October 2023

Posted:

01 November 2023

You are already at the latest version

Alerts
Abstract
Introduction: This analysis is conducted as a part of a quality improvement project aiming at identifying racial disparity in inpatient stroke quality of care. Methods: Get With The Guidelines (GWTG) database was used to identify all patients discharged with any stroke diagnosis between January and December 2021. Additional chart review was conducted to ensure the accuracy of racial/ethnic categorization. The sample was dichotomized to White vs non-White groups and compared with univariate analysis. Results: The study sample comprised 1,408 encounters (1,347 patients). Mean age 71±15 years, 51% women, 82% White patients, 15% non-White patients, 72% acute ischemic stroke (AIS); 15% transient ischemic attack (TIA), 9% intracerebral hemorrhage (ICH), 3% subarachnoid hemorrhage (SAH), and 1% stroke not otherwise specified. Non-White patients were younger, had fewer concomitant diagnoses, lower proportion of TIA and higher proportion of ICH (p=0.004). In AIS cohort, compared to White patients, non-White patients had less frequent ambulance (p=0.009), arrived to the hospital later than White patients (7.7 hours longer ; p<0.001), had more severe stroke, and had less frequent IV thrombolysis utilization (7% vs 13%; p=0.042). Similarly in the TIA cohort, non-White patients’ utilization of EMS was lower than White patients and their hospital arrival was delayed. In the ICH cohort, non-White patients were younger, had lower frequency of atrial fibrillation, and a non-significant trend towards higher disease severity. The SAH cohort had only 8 non-White patients, 6 of which were transferred to higher level of care hospital within a few hours of arrival, therefore. Importantly, the hospital-based quality metrics such as door-to-CT time, door-to-needle time, and the Joint Commission stroke quality metrics were similar between the two groups. Conclusion: There is a racial disparity in the pre-hospital phase of the stroke chain of survival of non-White patients impacting the IV thrombolysis utilization. The younger age and worse lipid profile and hemoglobin A1C of non-White patients suggest the need for better preventative care starting at young age.
Keywords: 
Subject: Medicine and Pharmacology  -   Neuroscience and Neurology

Introduction

Racial disparity in stroke outcome has been well documented. [1,2] While many of the factors contributing to this phenomenon, such as social determinants of health (SODH), [3,4] systemic racism, [5] suboptimal risk factors control, [6,7] and access to care, [8] are not under the control of the stroke center where patients are admitted for their stroke, the acute phase of stroke care is.
Racial disparity in acute stroke care has also been reported with lower rates of IV thrombolysis (IVT) [9,10] and mechanical thrombectomy (MT) utilization, [11,12] longer door-to-needle (DTN), [13,14] longer door-to-groin puncture (DTG) times, [15] less adherence to stroke quality metrics. [16]
Our healthcare organization operates 9 hospitals in the state of Minnesota with a stroke network that covers all 9 hospitals and serves over 3,500 stroke admissions annually. In 2022, 3 of our medical students wrote a paper on racial disparity in stroke as part of their Problems in Neurology class. Using data from one of our hospitals, they identified a significant disparity
in IVT utilization between White and African American patients (11.1% vs 5.1%, p<0.001). [17] While we had expected to find some difference between the two groups, the magnitude of difference was surprising and data available did not allow the exploration of possible causes. That analysis triggered a quality improvement project to better characterize and address the racial disparity in stroke care in our organization. Our current study was conducted as the first stage of this quality improvement project.

Materials and Methods

Our stroke network is composed of one academic comprehensive stroke center (CSC) and 8 community hospitals, including one thrombectomy-capable stroke center (TSC), one primary stroke center (PSC), and 6 stroke-ready hospitals. All hospitals follow the same internal stroke care guidelines, which are derived from the American Heart Association (AHA) guidelines, and are served by the same academic vascular neurology team.
For this analysis, we selected adult patients discharged with a stroke diagnosis, including acute ischemic stroke (AIS), transient ischemic attack (TIA), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH), in the calendar year 2021 from 2 of our community hospitals. The first is a TSC in Minneapolis, which provides stroke care for all patients except severe cases of SAH who are typically transferred to the CSC. The second is a PSC in St Paul which provides care for all stroke patient except large vessel occlusion who require MT who are transferred to either the CSC or TSC, ICH patients who require neurosurgical procedures, and all SAH who are transferred to CSC. These two hospitals where chosen because of high stroke volume and based on geographical location to ensure the inclusion of diverse population.
We used our institutional Get-With-The-Guidelines (GWTG) stroke registry to identify the study sample and extract the relevant variables for analysis. GWTG is a nationwide database maintained by the AHA and contains extensive information including prehospital care, vascular risk factors, acute stroke treatment, hospitalization outcome, and various quality metrics. GWTG is used in daily operations for quality monitoring. Only patients admitted through the emergency department (ED) were included. We excluded inpatient strokes, stroke mimics, and patients with incomplete GWTG records.
We used the GWTG database to collect and compare the following variables between White and non-White patients: age, sex, race/ethnicity, vascular risk factors, mode of arrival, initial vital signs, stroke severity scales (National Institutes of Health Stroke Scale [NIHSS] for AIS and TIA, and Glasgow Coma Scale [GCS] for ICH and SAH), ambulation status prior to index stroke which reflects baseline functional state, AIS treatments (IVT and MT), acute care quality metrics (e.g., DTN and DTG times), laboratory data (lipid profile, hemoglobin A1C, random serum glucose), brain and vascular imaging performance, electrocardiogram and echocardiogram performance, length of stay, hospital mortality, ambulation on discharge, and discharge disposition. Further retrospective review of the electronic medical records (EMR) was needed to confirm accuracy of the diagnosis and the race/ethnicity documented in GWTG and to abstract the following information: country of origin, primary language, and utilization of interpreters.
The study aim was to assess whether there is a difference in stroke quality of care between White and non-White patients. Patients with undocumented race/ethnicity, were categorized as non-White if their primary language was not English, or their country of origin was not US, or they needed an interpreter. The two study groups were compared using univariate analysis. Patients with unknown or undocumented race were included in the overall analysis but excluded from the comparative analysis. The following quality measures were compared between the two groups in all 4 stroke subtypes: last known well (LKW)-to-arrival time, door-to-CT performance time, mode of arrival (ambulance, private, transfer), documentation of stroke severity, length of stay, hospital mortality, discharge destination, ambulation on discharge, 30-day readmission, and 30-day mortality. Moreover, subtype-specific quality metrics were compared between the two study groups as follows:
AIS:
  • IVT utilization rate
  • MT utilization rate
  • DTN time
  • DTG time
  • The Joint Commission (TJC) stroke quality measures: STK1 (venous thromboembolism [VTE] prophylaxis), STK2 (discharge on antithrombotic therapy), STK3 (anticoagulation therapy for atrial fibrillation/flutter), STK4 (thrombolytic therapy), STK5 (antithrombotic therapy by end of hospital day 2), STK6 (discharged on statin medication), STK8 (stroke education), and STK10 (rehabilitation assessment).
TIA:
  • Completion of TIA workup: (1) brain magnetic resonance imaging (MRI), (2) vascular imaging of the head and neck with magnetic resonance angiography (MRA) or computed tomographic angiography (CTA), (3) echocardiogram transthoracic and/or transesophageal, (4) electrocardiogram, (5) lipid panel, (6) hemoglobin A1C. A scale from 0 to 6 was developed and calculated for each patient. A score of 6 out of 6 indicates performance of all 6 TIA tests.
ICH:
  • TJC quality measures: STK1, STK8, and STK10.
SAH:
  • Performance of vascular imaging (CTA, MRA)
  • TJC quality measures: STK1, STK8, and STK10.
The mean and standard deviation (SD) were reported for continuous variables and compared with t-test after testing for normality of data distribution using Q-Q plot and Shapiro-Wilk test. The median and interquartile range (IQR) were reported for continuous non-normally distributed variables and for non-parametric variables and were compared with Mann Whitney test. Frequency/percentages were reported for the categorical variables and were compared with chi-square test (or Fisher’s exact test if chi-squared assumptions are not met).
Missing data was identified and listed in supplementary material (tables S1-S5). Patients with missing data were excluded from the analyses of the variables they are missing but included in the analyses of the variables they have available. All p-values were 2-sided with statistical significance at 0.05.Statistical analysis was performed using SciPy Fundamental Algorithms for Scientific Computing in Python. Plots and graphs were produced using Matplotlib and Seaborn data visualization libraries in Python.
The study concept and methodology were reviewed by the institutional review board who deemed it to be a quality improvement project and allowed it to proceed without requiring full IRB review or subjects’ consent.

Results

There were 2,412 encounters in GWTG database within the study period. After excluding 874 stroke mimics, 61 inpatient strokes, 18 duplicate entries, and 51 records that could not be linked to EMR or were incomplete, the remaining 1,408 encounters of 1,347 patients represented the study sample (Figure 1).
Preprints 89316 g001
The study sample had a mean age 71±15 years, 51% women none of whom were pregnant, 82% White patients, 10% Asian, 4% Black, 1% Hispanic, 11% using non-English primary language, and 6% requiring interpreters Stroke subtypes were 72% AIS; 15% TIA, 9% ICH, 3% SAH, and 1% stroke not otherwise specified. Table 1 shows the basic demographic characteristics of the 4 stroke subtypes. The distribution of stroke subtypes was significantly different between White and non-White patients with more hemorrhagic stroke (ICH and SAH) in non-White patients and more TIA in White patients (p=0.004; Figure 2).
Regarding AIS cohort (1,019 encounters; 977 patients), compared to White patients, non-White patients were significantly younger (median [IQR] 66 [57-73] vs 75 {64-85] years; p<0.001), had fewer documented concomitant diagnoses (4 [2-5] vs 4 [3-5]; p=0.042), more patients with diabetes (45% vs 27%; p<0.001), higher hemoglobin A1c (6.3 [5.6-8.9]% vs 5.7 [5.4-6.3]%; p<0.001), especially in diabetics (8.5 [7-10]% vs 7.1 [6.3-8.1]%; p<0.001), fewer patients with dyslipidemia diagnosis (48% vs 60%; p=0.004) yet higher median LDL (99 [75-133] vs 84 [61-116] mg/dL; p<0.001), fewer atrial fibrillation (11% vs 21%; p=0.004), more history of prior stroke (35% vs 25%; p=0.006), lower frequency of emergency medical services (EMS) utilization (32% vs 44%; p=0.009), longer median time from LKW to arrival (856 [263-1921] vs 393 [93-1188]; p=0.001), higher mean diastolic blood pressure (DBP; 87 [78-99] vs 84 [74-96] mm Hg; p=0.033), higher initial NIHSS (3 [1-6] vs 2 [0-6]; p=0.023), and higher initial blood glucose (131 [109-188] vs 115 [100-143] mg/dl; p<0.001).
IVT utilization rate was lower in non-White patients (7% vs 13%; p=0.042), however, the rate was not statistically different when limited to patients presenting within 3.5 hours from LKW (32% vs 42%; p=0.433). The reasons for not administering IVT were documented in 78% of White and 88% of non-White patients. The most common IVT exclusion reason for both groups was inability to determine eligibility, usually due to unknown LKW time or inability to confirm inclusion/exclusion criteria (White; 316 [51%]; non-White 75 [67%]) while patient/family refusal was only documented in 7 (1.1%) of White and 2 (1.8%) of non-White. See Table S6.
In terms of hospitalization outcome, compared to White patients, non-White patients had fewer hospital mortality (1% vs 5%; p=0.029) and higher frequency of home discharge (69% vs 58%; p=0.011) despite having similar ambulatory status (p=0.927). Other quality metrics, including arrival-to-CT time, DTN time, DTG, MT utilization rate, and all STK metrics were not statistically significant (Table 2). Of note, there was no association between LKW time to arrival and DTN time (Pearson’s correlation coefficient -0.09; p=0.33; Figure S1).
Similar to the AIS cohort, the non-White patients in the ICH cohort (122 encounters; 121 patients) were younger (57 [43-63] vs 74 [64-82] years; p<0.001), had fewer documented concomitant diagnoses (2 [1-4] vs 4 [3-5]; p=0.003), fewer patients with dyslipidemia (29% vs 58%; p<0.011), and fewer patients with atrial fibrillation/flutter (0% vs 18%; p=0.012). Initial SBP, initial blood glucose, and intubation in the ED were numerically higher in the non-White group but were not statistically significant (tables 3). The in-hospital mortality rates, discharge disposition, and ambulatory status on discharge were not statistically different.
Table 3. Univariate analysis comparing White and non-White groups of the intracerebral hemorrhage cohort.
Table 3. Univariate analysis comparing White and non-White groups of the intracerebral hemorrhage cohort.
White Non-white p value
Sample size 91 27
Age in years, median (IQR) 74 (64-82) 57 (43-63) <0.001
Women, frequency (%) 41 (45%) 12 (43%) 1
Number of concomitant medical diagnoses, median (IQR) 4 (3-5) 2 (1-4) 0.003
Hypertension, frequency (%) 70 (77%) 17 (61%) 0.148
Diabetes mellitus, frequency (%) 20 (22%) 6 (21%) 1
Dyslipidemia, frequency (%) 53 (58%) 8 (29%) 0.011
Atrial fibrillation/flutter, frequency (%) 16 (18%) 0 0.012
Coronary artery disease, frequency (%) 18 (20%) 2 (7%) 0.154
Heart failure, frequency (%) 6 (7%) 1 (4%) 1
Current smoker, frequency (%) 6 (7%) 2 (7%) 1
Alcohol or illicit drug abuse, frequency (%) 11 (12%) 3 (11%) 1
Sleep apnea, frequency (%) 6 (7%) 1 (4%) 1
Overweight/obesity, frequency (%) 42 (46%) 17 (61%) 0.258
Prior stroke, frequency (%) 19 (21%) 7 (25%) 0.842
Family history of stroke, frequency (%) 17 (19%) 1 (4%) 0.069
Hemoglobin A1c (%), median (IQR) 7.3 (6.1-9.9) 8.2 (6.8-9.0) 1
Ambulatory status prior to index stroke, frequency (%) 0.531


● Independent ● 75 (95%0 ● 24 (100%)
● With assist ● 2 (3%) ● 0
● Unable ● 2 (3%) ● 0
Mode of arrival to the ED, frequency (%) 0.444
● EMS ● 51 (57%) ● 13 (50%)
● Private ● 17 (19%) ● 8 (31%)
● Hospital transfer ● 21 (24%) ● 5 (19%)
Time from last known well to ED arrival in minutes, median (IQR) 281 (83.5-838) 570 (72.5-792) 0.942
Time from ED arrival to CT performance in minutes, median (IQR) 27 (19-69.5) 41 (20-98.5) 0.3
SBP in mm Hg, median (IQR) 162 (138-190) 172 (140-202) 0.303
DBP in mm Hg, median (IQR) 90 (78-106) 85 (68-112) 0.412
Blood glucose in ED in mg/dL, median (IQR) 125 (106-162) 134 (128-174) 0.052
GCS score done on admission, frequency (%) 78 (86%) 21 (75%) 0.246
GCS score on admission, median (IQR) 15 (11-15) 12 (7-15) 0.308
IV antihypertensive use in the ED, frequency (%) 55 (65%) 19 (68%) 0.94
Intubation in the ED 10 (12%) 6 (22%) 0.222
External ventricular drain placement, frequency (%) 5 (6%) 4 (14%) 0.224
Decompressive craniectomy, frequency (%) 1 (1%) 1 (4%) 0.439
Hematoma evacuation, frequency (%) 5 (6%) 4 (14%) 0.224
Length of stay in hours, median (IQR) 84.4 (6.9-143.2) 41.3 (5.7-73.9) 0.069
In-hospital mortality, frequency (%) 17 (19%) 5 (18%) 1
Discharge destination, frequency (%) 0.830
● Home ● 15 (20%) ● 7 (30%)
● Rehab/nursing home ● 29 (39%) ● 7 (30%)
● Acute care hospital ● 23 (31%) ● 7 (30%)
● Hospice ● 7 (10%) ● 2 (9%)
● Against medical advice ● 0 ● 0
Ambulatory status at discharge, frequency (%) 0.834
● Independent ● 21 (42%) ● 5 (33%)
● With assist ● 26 (52%) ● 9 (60%)
● Unable ● 3 (6%) ● 1 (7%)
STK1: VTE prophylaxis 100% 92% 0.25
STK8: stroke education 91% 80% 1
STK10: rehabilitation assessment 100% 100% 1
IQR: interquartile range; EMS: emergency medical services; ED: emergency department; CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; GCS: Glasgow Coma Scale; IV: intravenous; STK: The Joint Commission (TJC) stroke quality metrics (note that we only selected the STKs relevant to ICH); VTE: venous thromboembolism;
In the TIA cohort (216 encounters; 212 patients), compared to White patients, non-White patients were younger (77 [64-84] vs 59 [51-77] years; p=0.003), had lower frequency of EMS utilization (11% vs 38%; p=0.016), higher hemoglobin A1C (6.1 [5.9-6.2] vs 5.5 [5.3-5.9]; p=0.002), and higher frequency of independent ambulation on discharge (93% vs 87%; p=0.011). No other characteristics were significantly different between the two groups including TIA workup completion (tables 4).
Table 4. Univariate analysis comparing White and non-White groups of the transient ischemic attack cohort.
Table 4. Univariate analysis comparing White and non-White groups of the transient ischemic attack cohort.
White Non-White p value
Sample size 212 19
Age in years, median (IQR) 77 (64-84) 59 (51-77) 0.003
Women, frequency (%) 117 (55%) 11 (58%) 1
Number of concomitant medical diagnoses, median (IQR) 3 (2-5) 3 (3-4) 0.579
Hypertension, frequency (%) 128 (65%) 13 (68%) 0.984
Diabetes mellitus, frequency (%) 40 (20%) 6 (32%) 0.252
Dyslipidemia, frequency (%) 120 (61%) 9 (47%) 0.351
Atrial fibrillation/flutter, frequency (%) 35 (18%) 1 (5%) 0.210
Coronary artery disease, frequency (%) 42 (21%) 2 (11%) 0.376
Heart failure, frequency (%) 16 (8%) 0 0.371
Current smoker, frequency (%) 9 (5%) 2 (11%) 0.252
Alcohol or illicit drug abuse, frequency (%) 6 (3%) 1 (5%) 0.482
Sleep apnea, frequency (%) 23 (12%) 1 (5%) 0.703
Overweight/obesity, frequency (%) 107 (55%) 9 (47%) 0.717
Prior stroke, frequency (%) 31 (16%) 3 (16%) 1.000
Family history of stroke, frequency (%) 21 (11%) 0 0.228
Hemoglobin A1c (%), median (IQR) 5.5 (5.3-5.9) 6.1 (5.9-6.2) 0.002
Hemoglobin A1c (%) in patients with known diabetes mellitus diagnosis, median (IQR) 7.0 (5.8-7.8) 6.6 (6.1-7.5) 0.918
LDL (mg/dL), median (IQR) 87 (64-115) 103 (77-126) 0.357
LDL (mg/dL) in patients with known dyslipidemia, median (IQR) 79 (58-113) 113 (68-141) 0.300
HDL (mg/dL), median (IQR) 49 (42-62) 42 (35-68) 0.175
HDL (mg/dL) in patients with known dyslipidemia, median (IQR) 49 (44-59) 43 (39-64) 0.491
Triglycerides (mg/dL), median (IQR) 117 (84-164) 138 (90-180) 0.539
Triglycerides (mg/dL) in patients with known dyslipidemia, median (IQR) 119 (89-163) 127 (98-158) 0.942
Total cholesterol (mg/dL), median (IQR)+A34:A43 164 (139-201) 180 (162-211) 0.272
Total cholesterol (mg/dL) in patients with known dyslipidemia, median (IQR) 158 (135-200) 178 (151-212) 0.348
Ambulatory status prior to index stroke, frequency (%) 0.108


● Independent ● 188 (99%) ● 17 (94%)
● With assist ● 1 (1%) ● 0
● Unable ● 1 (1%) ● 1 (6%)
Mode of arrival, frequency (%) 0.016
● EMS ● 73 (38%) ● 2 (11%)
● Private ● 105 (54%) ● 16 (89%)
● Hospital transfer ● 16 (8%) ● 0
Time from last known well to ED arrival in minutes, median (IQR) 132 (64-560) 165 (105-368) 0.203
Time from ED arrival to CT performance in minutes, median (IQR) 31 (17-64) 32 (29-39) 0.828
SBP in mm Hg, median (IQR) 156 (138-179) 152 (139-176) 0.587
DBP in mm Hg, median (IQR) 83 (75-94) 82 (70-100) 0.914
Blood glucose in ED in mg/dL, median (IQR) 108 (96-133) 117 (102-137) 0.421
Initial NIHSS documentation, frequency (%) 137 (70%) 13 (68%) 1.0
Initial NIHSS score, median (IRQ) 0 (0-1) 0 (0-1) 0.586
IV antihypertensive use in the ED, frequency (%) 8 (4%) 0 1.000
Intubation in the ED 0 0 1.000
TIA workup completeness score, median (IQR) 5 (3-6) 5 (2-6) 1.0
TIA workup 0.93
● Complete ● 67 (34%) ● 7 (37%)
● Partial ● 128 (65%) ● 12 (63%)
● Not done ● 1 (1%) ● 0
Length of stay in hours, median (IQR) 22.8 (5.3-46) 26.75 (23.6-46.1) 0.548
In-hospital mortality, frequency (%) 0 0 1
Discharge destination, frequency (%) 0.484
● Home ● 178 (91%) ● 18 (95%)
● Rehab/nursing home ● 12 (6%) ● 0
● Acute care hospital ● 6 (3%) ● 1 (5%)
● Hospice ● 0 ● 0
● Against medical advice ● 0 ● 0
Ambulatory status at discharge, frequency (%) 0.011


● Independent ● 86 (87%) ● 13 (93%)
● With assist ● 13 (13%) ● 0
● Unable ● 0 ● 1 (7%)
IQR: interquartile range; HDL: high density lipoprotein; LDL: low density lipoprotein; EMS: emergency medical services; ED: emergency department; CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; NIHSS: National Institutes of Health Stroke Scale; IV: intravenous; TIA: transient ischemic attack
Lastly, in the SAH cohort, which is the smallest cohort (41 encounters; 40 patients) with only 8 non-White patients, 6 of whom were transferred to higher level-of-care hospital, we could only make the following observations: compared to White patients, non-White patients had higher diastolic blood pressure (DBP; 81 [74-106] vs 114 [91-133] mm Hg; p=0.038), less frequently documented GCS (38% vs 94%; p=0.002), and a non-significant trend towards higher frequency of intubation in the ED (57% vs 19%; p=0.063). Other characteristics were not significantly different between the two groups including the performance of vascular imaging (tables 5).
Table 5. Univariate analysis comparing White and non-White groups of the subarachnoid hemorrhage cohort.
Table 5. Univariate analysis comparing White and non-White groups of the subarachnoid hemorrhage cohort.
White Non-White p value
Sample size 31 8
Age in years, median (IQR) 70 (57-84) 60 (48-75) 0.244
Women, frequency (%) 21 (68%) 6 (75%) 1
Number of concomitant medical diagnoses, median (IQR) 2 (1-3) 2 (1-3) 0.901
Hypertension, frequency (%) 14 (45%) 4 (50%) 1
Diabetes mellitus, frequency (%) 1 (3%) 2 (25%) 0.101
Dyslipidemia, frequency (%) 9 (29%) 4 (50%) 0.402
Atrial fibrillation/flutter, frequency (%) 3 (10%) 1 (13%) 1
Coronary artery disease, frequency (%) 3 (10%) 0 1
Heart failure, frequency (%) 1 (3%) 0 1
Current smoker, frequency (%) 4 (13%) 1 (13%) 1
Alcohol or illicit drug abuse, frequency (%) 1 (3%) 0 1
Sleep apnea, frequency (%) 3 (10%) 1 (13%) 1
Overweight/obesity, frequency (%) 13 (42%) 3 (38%) 1
Prior stroke, frequency (%) 4 (13%) 0 0.563
Family history of stroke, frequency (%) 3 (10%) 1 (13%) 1
Hemoglobin A1c (%), median (IQR) 5.6 (5.3-6.05) 5.4 (5.3-6.92) 0.98
Ambulatory status prior to index stroke, frequency (%) 1
● Independent ● 28 (97%) ● 7 (100%)
● With assist ● 1 (3%) ● 0
● Unable ● 0 ● 0
Mode of arrival to the ED, frequency (%) 0.184
● EMS ● 15 (52%) ● 7 (88%)
● Private ● 12 (41%) ● 1 (13%)
● Hospital transfer ● 2 (7%) ● 0
Time from last known well to hospital arrival in minutes, median (IQR) 808 (166-1749.5) 72 (59-1769.5) 0.862
Time from hospital arrival to CT performance in minutes, median (IQR) 64 (35.25-98.25) 33 (28-47.5) 0.112
SBP in mm Hg, median (IQR) 154 (131-168) 118 (103-192) 0.379
DBP in mm Hg, median (IQR) 81 (74-106) 114 (91-133) 0.038
Blood glucose in ED in mg/dL, median (IQR) 115 (94-157) 139 (123-150) 0.325
GCS on admission, median (IQR) 15 (12-15) 15 (9-15) 0.813
GCS documented on admission, frequency (%) 29 (94%) 3 (38%) 0.002
IV antihypertensive use in the ED, frequency (%) 8 (4%) 0 1
Intubation in the ED 6 (19%) 4 (57%) 0.063
External ventricular drain placement, frequency (%) 8 (26%) 2 (29%) 1
Performance of CTA or MRA 25 (81%) 6 (75.0%) 0.658
Aneurysm coiling, frequency (%) 7 (23%) 2 (29%) 1
Aneurysm clipping, frequency (%) 3 (10%) 0 1
Length of stay in hours, median (IQR) 27.6 (5.7-71.1) 3 (1.9-5.4) 0.035
In-hospital mortality, frequency (%) 2 (6%) 1 (13%) 0.508
Discharge destination, frequency (%) 0.481
● Home ● 8 (28%) ● 1 (14%)
● Rehab/nursing home ● 4 (14%) ● 0
● Acute care hospital ● 16 (55%) ● 6 (86%)
● Hospice ● 9 (31%) ● 0
● Against medical advice ● 0 ● 0
IQR: interquartile range; EMS: emergency medical services; ED: emergency department; CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; GCS: Glasgow Coma Scale; IV: intravenous; CTA: computed tomographic angiogram; MRA: magnetic resonance angiogram

Discussion

In this retrospective analysis of patients admitted with stroke, we found racial disparity in the pre-hospital phase of care (less EMS utilization and delayed arrival) and vascular risk factors control (dyslipidemia and diabetes mellitus). However, the quality of care delivered at the hospitals was largely similar between the White and non-White patients.
Our study’s racial composition is unique in that out of the 15% non-White patients, 10% were Asian and only 4% were black. The relatively high Asian population is due to the high concentration of the Hmong population in the catchment area of the study hospitals, especially in the city of St Paul where 19% of the population is Asian. [18] Stroke in Hmong-Americans was first characterized in a recent retrospective study. [19] There are multiple similarities between this current analysis and stroke in Hmong-Americans which we will highlight in the relevant sections of this discussion.
We observed that the median age of non-White patients was 11 years younger than that of White patients’, which is the same difference observed between Hmong-Americans and White patients. [19] Non-White patients with ICH have the youngest median age compared to non-White patients of other stroke subtypes. We also observed that the proportion of ICH was higher in the non-White group, which is consistent with findings in Hmong-Americans, [19] other Asian ethnicities, such as Japanese [20] and Chinese, [21] and Asian-Americans in general. [22,23] This means that a larger proportion of younger non-White patients suffer ICH, which is a disease with higher morbidity and mortality [24] and, unlike AIS, has no effective therapeutic intervention. [25]
Our most important observation is the break in the stroke chain of survival at its first link. The stroke chain of survival starts with symptom recognition and calling 911 which activates EMS leading to emergent transport of patients to appropriate hospital and increasing the chances of providing reperfusion therapies. [26] Overall, the rate of EMS utilization in non-White patients was lowest in TIA, the least severe stroke subtype, and highest in the most severe stroke subtypes, ICH and SAH. These observations raise the concern that the non-White patients have lower tendency to seek emergent care in cases of mild or transient symptoms, which would be a missed opportunity in averting a disabling stroke. It is well known that the risk of stroke is high after TIA. A recent analysis of the Framingham study calculated an adjusted hazard ratio of 4.37 of TIA patients suffering a subsequent stroke compared to matched control participants who did not have a TIA. [27] This is why the AHA guidelines recommend rapid evaluation of TIA and initiation of secondary stroke prevention. [28] Early arrival is also important for AIS to increase the chances, maximize the benefit, and minimize the complications of IV thrombolysis administration. [29]
The low rate of EMS utilization in non-White patients with AIS and TIA and the significant delay in arrival is similar to the observed delay in Hmong-Americans [19] and racial minorities in general. [30,31] We recently conducted a stroke health literacy survey within the Hmong community and found that while 95% of respondents could name at least one correct stroke symptom, only 78% indicated that the first action they would take in the case of a stroke would be to call 911. [32] Therefore, health literacy gap could explain, at least partially, the difference in EMS utilization. Another important factor is ambulance cost. A recent analysis showed rising cost of ambulance utilization from 2007 to 2018 among Medicare beneficiaries (up to $1,700 per ride), [33] which may deter individuals of lower socioeconomic states from seeking EMS care. We also heard from the Hmong community during various community engagement events that some Hmong individuals do not feel comfortable interacting with any person in a uniform owing to prior historical trauma.
EMS utilization rates were not different between White and non-White patients with ICH and were higher for both groups compared to their AIS counterparts. This might be related to the higher disease severity given the non-significantly higher proportion of intubation in the ICH group compared to the AIS group. Similarly, the time from LKW to ED arrival was not statistically different between White and non-White ICH patients although the median was numerically higher in the non-White group (about 4 hours longer). These findings resemble those of stroke in Hmong-Americans except that the EMS utilization was actually significantly higher and the disease severity, as measured by NIHSS and GCS, was significantly higher in the Hmong-American patients compared to White patients. [19]
Numerous studies have reported the racial disparity in IVT utilization rate. [1,9,10,34,35] We observed the same phenomenon (7% in non-White vs 13% in White; p=0.042), which is not surprising given the delay in ED arrival in case of the non-White group. This finding is also similar to that of the stroke in Hmong-Americans study in which the utilization rate was 6% in Hmong patients and 14% in White patients (p=0.03496), [19] and a nationwide GWTG analysis that included 64,337 Asian American patients and showed lower IVT utilization rates compared to White patients (odds ratio 0.95; 95% confidence interval 0.91-0.98; p=0.003). [35] When we limited the comparison to patients who presented within 3.5 hours from LKW, allowing the clinical team one hour for evaluation and treatment, there was no statistical difference between White and non-White groups, which further supports the relationship between delay in arrival and the low rate of IVT.
It is important to point out that the 2 most common reasons for not administering IVT were similar in both groups. The first is the inability to determine eligibility which includes patients with unclear diagnosis, patients with unknown time of onset, and patients in whom the inclusion/exclusion criteria cannot be confirmed. The second is mild stroke deficit. These 2 reasons were documented in over three quarters of the patients who were not treated with thrombolysis in each group. The rate of refusal of IVT was similarly low in both groups, unlike other studies showing higher rate of refusal in racial minorities. [36,37] However, in those studies, the finding was mainly driven by African American patients who represent only 4% of our AIS cohort.
Aside from the lower IVT utilization rate attributable to delay in arrival, the hospital-based quality metrics were not different between White and non-White patients with the exception of the GCS documentation in SAH which was lower in non-White, probably related to higher disease severity, intubation, and transfer to CSC (median length of stay 3 hours).We did not find a difference in the MT utilization rate. While this may be related to the small sample size, the extended treatment window of MT (up to 24 hours from LKW) [38] may have allowed the intervention in non-White patients who arrived beyond the IVT window. Other studies have shown lower rate of MT in racial minorities but these were primarily driven by African American and Hispanic patients. [10,11,12] TIA workup was similar between White and non-White groups. A recent study showed suboptimal care of African American TIA patients compared to White patients with lower rates of brain and vascular imaging except in those who have been cared for by a neurologist. [39]
We observe important differences in vascular risk factors control between White and non-White groups in the AIS group. Hemoglobin A1c and lipid profile were worse in the non-White group. The same pattern can be observed when the analysis is limited to those with known diabetes mellitus, in the case of hemoglobin A1c and dyslipidemia in the case of lipid profile. These observations are consistent with many studies indicating undertreatment of cardiovascular risk factors in racial minorities. For example, an analysis of the 2013 Medical Expenditure Survey showed lower diabetes quality of care in racial minorities, particularly hemoglobin A1c monitoring, which was attributed to socioeconomic state and access to healthcare. [40] Another study found lower rates of utilization of new antidiabetic drugs irrespective of socioeconomic status. [41] As for dyslipidemia, data from the Behavioral Risk Factor Surveillance System showed that lower socioeconomic status, lack of healthcare access and language barriers explained most of the racial and ethnic disparities in cholesterol screening. [42] And in a recent study that analyzed National Health and Nutrition Examination Survey (NHANES) data from 2007 to 2018, improvement of lipid profile was noted in all racial/ethnic groups except Asian. [43] In fact, SDOH entirely accounted for the disparity in cardiovascular mortality in another NHANES analysis using data from 1999 to 2018. [44]
We do not have data comparing hypertension control between our two study groups prior to the index stroke. However, racial disparity in hypertension is well documented. [45,46] Relevant to our study is a recent analysis of 259,824 hypertensive ambulatory patients in Minnesota, the rate of uncontrolled hypertension was highest in Hmong, African American, and Somali patients. [47]
Our study has important limitations, including the retrospective design and the small sample size. The data source is a quality database, not a research one. We did not have control on GWTG data abstraction and only accessed the charts to confirm the race and other relevant variables but did not verify the accuracy of other variables or complete any missing values. We were unable to follow the recommended disaggregation of races/ethnicities [48] and combined all non-White patients in one group because of the small sample size which might have obscured important inter-racial differences.
This analysis is part of quality improvement efforts to address racial disparity at our stroke system of care. Our plan to mitigate the disparity has two main components. The first is to address the break in the stroke chain of survival by engaging with the racial minority communities to improve stroke health literacy and encourage the use of EMS, and the second is to engage with local healthcare systems and primary care providers to improve primary prevention. We have already shared the results of this study internally through multiple lectures and conferences on the topic including one lecture in which one of our stroke survivors from a racial minority shared the stroke admission experience and provided feedback about areas of improvement. We also shared the results of this analysis with the Cardiovascular Health Alliance of the Minnesota Department of Health. We participated in a health-focused podcast with one of our stroke survivors from a racial minority and discussed the issue of racial disparity in stroke. We also have upcoming speaking events targeting primary care providers in clinics that provide care to racial minority groups. At the community-level, we have reached out to multiple community organizations of racial minority groups. We have an ongoing research project utilizing the University of Minnesota Mobile Health Initiative to identify individuals with elevated blood pressure and provide them with self-monitoring blood pressure measuring devices. After the results of this analysis, we decided to add stroke education to the educational material we are providing.

Conclusion

The disparity in acute stroke care is mainly driven by delayed hospital arrival and low EMS utilization. Efforts are needed to engage with racial minority communities to improve health literacy and encourage EMS utilization. Some vascular risk factors control is worse in non-White patients suggesting the need for more rigorous primary care.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Table S1: Frequency and percent of missing data for the whole sample cohort; Table S2: Frequency and percent of missing data for the acute ischemic stroke cohort; Table S3: Frequency and percent of missing data for the transient ischemic attack cohort; Table S4: Frequency and percent of missing data for the intracerebral hemorrhage cohort; Table S5: Frequency and percent of missing data for the subarachnoid hemorrhage cohort; Table S6: Reasons for not administering IV thrombolysis; Figure S1: Scatterplot showing the last-known-well-to-arrival time and the door-to-needle time in patients who received IV thrombolysis.

Author Contributions

Conceptualization, H.M.H.; Methodology, H.M.H.; Validation, M.K.Y; Formal Analysis, A.E.; Data Curation M.K.Y, S.R., R.S., O.L., Y.O, J.L; Writing – Original Draft Preparation, H.M.H.; Writing – Review & Editing, M.K.Y, S.R., R.S., Y.O. A.E.; Visualization, S.R, A.E.; Supervision, H.M.H.; Project Administration, S.R., M.K.Y.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki. The Institutional Review Board of the University of Minnesota reviewed the study’s aim, scope, and methodology (IRB # STUDY00015365), determined that it met the criteria for quality improvement rather than human subjects research, and allowed the analysis to proceed without requiring full IRB application/approval or patients’ consent. .

Informed consent

not applicable.

Data availability

Raw data are available from the corresponding author on reasonable request, following approval from the relevant data custodians.

Financial Conflict of Interest

The authors declare no conflict of interest.

References

  1. de Havenon, A.; Zhou, L.W.; Johnston, K.C.; Dangayach, N.S.; Ney, J.; Yaghi, S.; Sharma, R.; Abbasi, M.; Delic, A.; Majersik, J.J.; et al. Twenty-Year Disparity Trends in United States Stroke Death Rate by Age, Race/Ethnicity, Geography, and Socioeconomic Status. Neurology 2023, 101, e464–e474. [Google Scholar] [CrossRef] [PubMed]
  2. Ariss, R.W.; Minhas, A.M.K.; Lang, J.; Ramanathan, P.K.; Khan, S.U.; Kassi, M.; Warraich, H.J.; Kolte, D.; Alkhouli, M.; Nazir, S. Demographic and Regional Trends in Stroke-Related Mortality in Young Adults in the United States, 1999 to 2019. J. Am. Heart Assoc. 2022, 11, e025903. [Google Scholar] [CrossRef] [PubMed]
  3. Reshetnyak, E.; Ntamatungiro, M.; Pinheiro, L.C.; Howard, V.J.; Carson, A.P.; Martin, K.D.; Safford, M.M. Impact of Multiple Social Determinants of Health on Incident Stroke. Stroke 2020, 51, 2445–2453. [Google Scholar] [CrossRef] [PubMed]
  4. Khan, S.U.; Acquah, I.; Javed, Z.; Valero-Elizondo, J.; Yahya, T.; Blankstein, R.; Virani, S.S.; Blaha, M.J.; Hyder, A.A.; Dubey, P.; et al. Social Determinants of Health Among Non-Elderly Adults With Stroke in the United States. Mayo Clin. Proc. 2022, 97, 238–249. [Google Scholar] [CrossRef] [PubMed]
  5. Levine, D.A.; Duncan, P.W.; Nguyen-Huynh, M.N.; Ogedegbe, O.G. Interventions Targeting Racial/Ethnic Disparities in Stroke Prevention and Treatment. Stroke 2020, 51, 3425–3432. [Google Scholar] [CrossRef] [PubMed]
  6. Gu, A.; Yue, Y.; Desai, R.P.; Argulian, E. Racial and Ethnic Differences in Antihypertensive Medication Use and Blood Pressure Control Among US Adults With Hypertension: The National Health and Nutrition Examination Survey, 2003 to 2012. Circ. Cardiovasc. Qual. Outcomes 2017, 10, e003166. [Google Scholar] [CrossRef] [PubMed]
  7. Clements, J.M.; West, B.T.; Yaker, Z.; Lauinger, B.; McCullers, D.; Haubert, J.; Tahboub, M.A.; Everett, G.J. Disparities in Diabetes-Related Multiple Chronic Conditions and Mortality: The Influence of Race. Diabetes Res. Clin. Pract. 2020, 159, 107984. [Google Scholar] [CrossRef] [PubMed]
  8. Bekelis, K.; Missios, S.; MacKenzie, T.A. Access Disparities to Magnet Hospitals for Ischemic Stroke Patients. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2017, 43, 68–71. [Google Scholar] [CrossRef] [PubMed]
  9. Suolang, D.; Chen, B.J.; Wang, N.-Y.; Gottesman, R.F.; Faigle, R. Geographic and Regional Variability in Racial and Ethnic Disparities in Stroke Thrombolysis in the United States. Stroke 2021, 52, e782–e787. [Google Scholar] [CrossRef]
  10. Otite, F.O.; Saini, V.; Sur, N.B.; Patel, S.; Sharma, R.; Akano, E.O.; Anikpezie, N.; Albright, K.; Schmidt, E.; Hoffman, H.; et al. Ten-Year Trend in Age, Sex, and Racial Disparity in tPA (Alteplase) and Thrombectomy Use Following Stroke in the United States. Stroke 2021, 52, 2562–2570. [Google Scholar] [CrossRef]
  11. Kim, Y.; Sharrief, A.; Kwak, M.J.; Khose, S.; Abdelkhaleq, R.; Salazar-Marioni, S.; Zhang, G.-Q.; Sheth, S.A. Underutilization of Endovascular Therapy in Black Patients With Ischemic Stroke: An Analysis of State and Nationwide Cohorts. Stroke 2022, 53, 855–863. [Google Scholar] [CrossRef] [PubMed]
  12. Sheriff, F.; Xu, H.; Maud, A.; Gupta, V.; Vellipuram, A.; Fonarow, G.C.; Matsouaka, R.A.; Xian, Y.; Reeves, M.; Smith, E.E.; et al. Temporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke. J. Am. Heart Assoc. 2022, 11, e023212. [Google Scholar] [CrossRef] [PubMed]
  13. Ajinkya, S.; Almallouhi, E.; Turner, N.; Al Kasab, S.; Holmstedt, C.A. Racial/Ethnic Disparities in Acute Ischemic Stroke Treatment Within a Telestroke Network. Telemed. J. E-Health Off. J. Am. Telemed. Assoc. 2020, 26, 1221–1225. [Google Scholar] [CrossRef] [PubMed]
  14. Oluwole, S.A.; Wang, K.; Dong, C.; Ciliberti-Vargas, M.A.; Gutierrez, C.M.; Yi, L.; Romano, J.G.; Perez, E.; Tyson, B.A.; Ayodele, M.; et al. Disparities and Trends in Door-to-Needle Time. Stroke 2017, 48, 2192–2197. [Google Scholar] [CrossRef] [PubMed]
  15. Siegler, J.E.; Ortega-Gutierrez, S.; Hester, T.; Haussen, D.C.; Nogueira, R.G.; Liebeskind, D.S.; Zaidat, O.O.; Vora, N.; Desai, S.; Jadhav, A.P.; et al. Interaction of Ethnicity and Arrival Method on Thrombectomy Delay: The Society of Vascular and Interventional Neurology Collaboration. Stroke Vasc. Interv. Neurol. 2022, 2, e000217. [Google Scholar] [CrossRef]
  16. Schwamm, L.H.; Reeves, M.J.; Pan, W.; Smith, E.E.; Frankel, M.R.; Olson, D.; Zhao, X.; Peterson, E.; Fonarow, G.C. Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke. Circulation 2010, 121, 1492–1501. [Google Scholar] [CrossRef] [PubMed]
  17. Banks, Evan; Rasner, C. ; Leslie, A.; Hussein, H.M. The Devastating Effects Of Racial Disparities In Acute Stroke Management: Where We Stand Now. Minn. Med. Mag. 2023, 4, 10–14. [Google Scholar]
  18. U.S. Census Bureau QuickFacts: St. Paul City, Minnesota. Available online: https://www.census.gov/quickfacts/fact/table/stpaulcityminnesota/PST045222 (accessed on 5 October 2023).
  19. Hussein, H.M.; Kashyap, B.; O’Keefe, L.; Droegemueller, C.; Othman, S.I.; Yang, M.K.; Hanson, L.R. Stroke Characteristics in a Cohort of Hmong American Patients. J. Am. Heart Assoc. 2023, 12, e026763. [Google Scholar] [CrossRef]
  20. Suzuki, K.; Izumi, M. The Incidence of Hemorrhagic Stroke in Japan Is Twice Compared with Western Countries: The Akita Stroke Registry. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2015, 36, 155–160. [Google Scholar] [CrossRef]
  21. Tsai, C.-F.; Anderson, N.; Thomas, B.; Sudlow, C.L.M. Comparing Risk Factor Profiles between Intracerebral Hemorrhage and Ischemic Stroke in Chinese and White Populations: Systematic Review and Meta-Analysis. PloS One 2016, 11, e0151743. [Google Scholar] [CrossRef]
  22. Klatsky, A.L.; Friedman, G.D.; Sidney, S.; Kipp, H.; Kubo, A.; Armstrong, M.A. Risk of Hemorrhagic Stroke in Asian American Ethnic Groups. Neuroepidemiology 2005, 25, 26–31. [Google Scholar] [CrossRef] [PubMed]
  23. van Asch, C.J.; Luitse, M.J.; Rinkel, G.J.; van der Tweel, I.; Algra, A.; Klijn, C.J. Incidence, Case Fatality, and Functional Outcome of Intracerebral Haemorrhage over Time, According to Age, Sex, and Ethnic Origin: A Systematic Review and Meta-Analysis. Lancet Neurol. 2010, 9, 167–176. [Google Scholar] [CrossRef] [PubMed]
  24. Jolink, W.M.T.; Klijn, C.J.M.; Brouwers, P.J.A.M.; Kappelle, L.J.; Vaartjes, I. Time Trends in Incidence, Case Fatality, and Mortality of Intracerebral Hemorrhage. Neurology 2015, 85, 1318–1324. [Google Scholar] [CrossRef] [PubMed]
  25. Greenberg, S.M.; Ziai, W.C.; Cordonnier, C.; Dowlatshahi, D.; Francis, B.; Goldstein, J.N.; Hemphill, J.C.; Johnson, R.; Keigher, K.M.; Mack, W.J.; et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke 2022, 53, e282–e361. [Google Scholar] [CrossRef] [PubMed]
  26. Puolakka, T.; Strbian, D.; Harve, H.; Kuisma, M.; Lindsberg, P.J. Prehospital Phase of the Stroke Chain of Survival: A Prospective Observational Study. J. Am. Heart Assoc. 2016, 5, e002808. [Google Scholar] [CrossRef] [PubMed]
  27. Lioutas, V.-A.; Ivan, C.S.; Himali, J.J.; Aparicio, H.J.; Leveille, T.; Romero, J.R.; Beiser, A.S.; Seshadri, S. Incidence of Transient Ischemic Attack and Association With Long-Term Risk of Stroke. JAMA 2021, 325, 373–381. [Google Scholar] [CrossRef] [PubMed]
  28. Amin, H.P.; Madsen, T.E.; Bravata, D.M.; Wira, C.R.; Johnston, S.C.; Ashcraft, S.; Burrus, T.M.; Panagos, P.D.; Wintermark, M.; Esenwa, C.; et al. Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement From the American Heart Association. Stroke 2023, 54, e109–e121. [Google Scholar] [CrossRef] [PubMed]
  29. Saver, J.L.; Fonarow, G.C.; Smith, E.E.; Reeves, M.J.; Grau-Sepulveda, M.V.; Pan, W.; Olson, D.M.; Hernandez, A.F.; Peterson, E.D.; Schwamm, L.H. Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke. JAMA 2013, 309, 2480–2488. [Google Scholar] [CrossRef]
  30. Mochari-Greenberger, H.; Xian, Y.; Hellkamp, A.S.; Schulte, P.J.; Bhatt, D.L.; Fonarow, G.C.; Saver, J.L.; Reeves, M.J.; Schwamm, L.H.; Smith, E.E. Racial/Ethnic and Sex Differences in Emergency Medical Services Transport Among Hospitalized US Stroke Patients: Analysis of the National Get With The Guidelines-Stroke Registry. J. Am. Heart Assoc. 2015, 4, e002099. [Google Scholar] [CrossRef]
  31. Springer, M.V.; Labovitz, D.L.; Hochheiser, E.C. Race-Ethnic Disparities in Hospital Arrival Time after Ischemic Stroke. Ethn. Dis. 27, 125–132. [CrossRef]
  32. Hussein, H.M.; Droegemueller, C.; Xiong, P.; Xiong, Z.; Dyke, S.V.; Mueller-Hussein, J. Hmong Stroke Knowledge Survey. J. Health Care Poor Underserved 2022, 33, 2052–2059. [Google Scholar] [CrossRef]
  33. Birmingham, L.E.; Arens, A.; Longinaker, N.; Kummet, C. Trends in Ambulance Transports and Costs among Medicare Beneficiaries, 2007-2018. Am. J. Emerg. Med. 2021, 47, 205–212. [Google Scholar] [CrossRef] [PubMed]
  34. Asaithambi, G.; Tong, X.; Coleman King, S.M.; George, M.G. Contemporary Trends in the Treatment of Mild Ischemic Stroke with Intravenous Thrombolysis: Paul Coverdell National Acute Stroke Program. Cerebrovasc. Dis. Basel Switz. 2022, 51, 60–66. [Google Scholar] [CrossRef] [PubMed]
  35. Song, S.; Liang, L.; Fonarow, G.C.; Smith, E.E.; Bhatt, D.L.; Matsouaka, R.A.; Xian, Y.; Schwamm, L.H.; Saver, J.L. Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke. JAMA Neurol. 2019, 76, 430–439. [Google Scholar] [CrossRef] [PubMed]
  36. Mendelson, S.J.; Aggarwal, N.T.; Richards, C.; O’Neill, K.; Holl, J.L.; Prabhakaran, S. Racial Disparities in Refusal of Stroke Thrombolysis in Chicago. Neurology 2018, 90, e359–e364. [Google Scholar] [CrossRef] [PubMed]
  37. Mendelson, S.J.; Zhang, S.; Matsouaka, R.; Xian, Y.; Shah, S.; Lytle, B.L.; Solomon, N.; Schwamm, L.H.; Smith, E.E.; Saver, J.L.; et al. Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke. Neurology 2022, 98, e1596–e1604. [Google Scholar] [CrossRef] [PubMed]
  38. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418. [Google Scholar] [CrossRef] [PubMed]
  39. Mitchell, J.B.; Ballard, D.J.; Matchar, D.B.; Whisnant, J.P.; Samsa, G.P. Racial Variation in Treatment for Transient Ischemic Attacks: Impact of Participation by Neurologists. Health Serv. Res. 2000, 34, 1413–1428. [Google Scholar] [PubMed]
  40. Canedo, J.R.; Miller, S.T.; Schlundt, D.; Fadden, M.K.; Sanderson, M. Racial/Ethnic Disparities in Diabetes Quality of Care: The Role of Healthcare Access and Socioeconomic Status. J. Racial Ethn. Health Disparities 2018, 5, 7–14. [Google Scholar] [CrossRef] [PubMed]
  41. Elhussein, A.; Anderson, A.; Bancks, M.P.; Coday, M.; Knowler, W.C.; Peters, A.; Vaughan, E.M.; Maruthur, N.M.; Clark, J.M.; Pilla, S. Racial/Ethnic and Socioeconomic Disparities in the Use of Newer Diabetes Medications in the Look AHEAD Study. Lancet Reg. Health - Am. 2021, 6, 100111. [Google Scholar] [CrossRef]
  42. Kenik, J.; Jean-Jacques, M.; Feinglass, J. Explaining Racial and Ethnic Disparities in Cholesterol Screening. Prev. Med. 2014, 65, 65–69. [Google Scholar] [CrossRef]
  43. Aggarwal, R.; Bhatt, D.L.; Rodriguez, F.; Yeh, R.W.; Wadhera, R.K. Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018. JAMA 2022, 328, 737–745. [Google Scholar] [CrossRef] [PubMed]
  44. He, J.; Bundy, J.D.; Geng, S.; Tian, L.; He, H.; Li, X.; Ferdinand, K.C.; Anderson, A.H.; Dorans, K.S.; Vasan, R.S.; et al. Social, Behavioral, and Metabolic Risk Factors and Racial Disparities in Cardiovascular Disease Mortality in U.S. Adults. Ann. Intern. Med. 2023, 176, 1200–1208. [Google Scholar] [CrossRef] [PubMed]
  45. Aggarwal, R.; Chiu, N.; Wadhera, R.K.; Moran, A.E.; Raber, I.; Shen, C.; Yeh, R.W.; Kazi, D.S. Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertens. Dallas Tex 1979 2021, 78, 1719–1726. [Google Scholar] [CrossRef] [PubMed]
  46. Rana, J.; Oldroyd, J.; Islam, Md.M.; Tarazona-Meza, C.E.; Islam, R.M. Prevalence of Hypertension and Controlled Hypertension among United States Adults: Evidence from NHANES 2017-18 Survey. Int. J. Cardiol. Hypertens. 2020, 7, 100061. [Google Scholar] [CrossRef]
  47. Hussein, H.M.; Chrenka, E.; Yang, M.K.; Margolis, K.L.; Kottke, T.E. Describing Racial Disparity in Hypertension Control in a Large Minnesota Outpatient Practice. Health Serv. Res. Manag. Epidemiol. 2023, 10, 23333928231192830. [Google Scholar] [CrossRef]
  48. Flanagin, A.; Frey, T.; Christiansen, S.L. ; AMA Manual of Style Committee Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. JAMA 2021, 326, 621–627. [Google Scholar] [CrossRef]
Figure 2. Stroke subtypes by race.
Figure 2. Stroke subtypes by race.
Preprints 89316 g002
Table 1. Basic demographic characteristics of the 4 disease states included in the analysis.
Table 1. Basic demographic characteristics of the 4 disease states included in the analysis.
AIS TIA ICH SAH
Sample size 1019 216 122 41
Mean age 72±15 72±15 68±17 67±16
Female sex 51% 57% 44% 70%
Non-White 15% 7% 22% 20%
Countries of origin United States 87%
Laos 6%
Russia 1%
Myanmar 1%
Vietnam 1%
Cambodia 1%
United States 92%
Laos 2%
United Kingdom 1%
Cambodia 1%
United States 82%
Laos 4%
Somalia 3%
Cambodia 2%
Philippines 2%
Myanmar 2%
Mexico 2%
United States 85%,
Vietnam 10%
Cambodia 3%
Laos 3%
Non-English primary language 11% 5% 13% 15%
Need for interpretation 7% 2% 7% 5%
AIS: acute ischemic stroke; TIA: transient ischemic attack; ICH: intracerebral hemorrhage; SAH: subarachnoid hemorrhage
Table 2. Univariate analysis comparing White and non-White groups of the acute ischemic stroke cohort.
Table 2. Univariate analysis comparing White and non-White groups of the acute ischemic stroke cohort.
White Non-White p value
Sample size 860 173
Age in years, median (IQR) 75 (64-85) 66 (57-73) <0.001
Women, median (IQR) 424 (51%) 81 (48%) 0.713
Number of concomitant medical diagnoses, median (IQR) 4 (3-5) 4 (2-5) 0.042
Hypertension, frequency (%) 600 (72%) 119 (72%) 1.000
Diabetes mellitus, frequency (%) 224 (27%) 78 (45%) <0.001
Dyslipidemia, frequency (%) 502 (60%) 79 (48%) 0.004
Atrial fibrillation/flutter, frequency (%) 175 (21%) 18 (11%) 0.004
Coronary artery disease, frequency (%) 186 (22%) 17 (10%) 0.001
Heart failure, frequency (%) 84 (10%) 11 (7%) 0.220
Current smoker, frequency (%) 111 (13%) 19 (12%) 0.610
Alcohol or illicit drug abuse, frequency (%) 66 (8%) 9 (5%) 0.347
Sleep apnea, frequency (%) 96 (12%) 11 (7%) 0.087
Overweight/obesity, frequency (%) 451 (54%) 84 (51%) 0.490
Prior stroke, frequency (%) 211 (25%) 58 (35%) 0.006
Family history of stroke, frequency (%) 87 (10%) 13 (8%) 0.387
Hemoglobin A1c (%), median (IQR) 5.7 (5.4-6.3) 6.3 (5.6-8.9) <0.001
Hemoglobin A1c (%) in patients with known diabetes mellitus diagnosis, median (IQR) 7.1 (6.3-8.1) 8.5 (7.0-10.0) <0.001
LDL (mg/dL), median (IQR) 84 (61-116) 99 (75-133) <0.001
LDL (mg/dL) in patients with known dyslipidemia, median (IQR) 78 (55-111) 99 (75-134) <0.001
HDL (mg/dL), median (IQR) 47 (38-58) 44 (37-54) 0.066
HDL (mg/dL) in patients with known dyslipidemia, median (IQR) 45 (38-58) 45 (40-54) 0.932
Triglycerides (mg/dL), median (IQR) 112 (81-161) 125 (85-184) 0.033
Triglycerides (mg/dL) in patients with known dyslipidemia, median (IQR) 114 (82-166) 132 (91-186) 0.047
Total cholesterol (mg/dL), median (IQR) 160 (132-194) 176 (144-210) <0.001
Total cholesterol (mg/dL) in patients with known dyslipidemia, median (IQR) 154 (126-188) 180 (150-211) <0.001
Ambulatory status prior to index stroke, frequency (%) 0.841
● Independent ● 722 (91%) ● 146 (92%)
● With assist ● 47 (6%) ● 9 (6%)
● Unable ● 27 (3%) ● 4 (3%)
Mode of arrival, frequency (%) 0.009
● EMS ● 342 (44%) ● 50 (32%)
● Private ● 279 (39%) ● 79 (51%)
● Hospital transfer ● 131 (17%) ● 26 (17%)
Time from last known well to ED arrival in minutes, median (IQR) 393 (93-1188) 856 (263-1921) 0.001
Time from ED arrival to CT performance in minutes, median (IQR) 20 (15-28) 17 (14-20) 0.163
Door-to-needle time in minutes, median (IQR) 65 (46-88) 56 (41-132) 0.832
Door-to-groin time in minutes, median (IQR) 112 (101-123) 134 (101-190) 0.342
SBP in mm Hg, median (IQR) 155 (137-173) 158 (137-182) 0.114
DBP in mm Hg, median (IQR) 84 (74-96) 87 (78-99) 0.033
Blood glucose in ED in mg/dL, median (IQR) 115 (100-143) 131 (109-188) <0.001
Initial NIHSS documentation, frequency (%) 625 (75%) 119 (72%) 0.477
Initial NIHSS score, median (IRQ) 2 (0-6) 3 (1-6) 0.023
Initial NIHSS score for IVT patients, median (IRQ) 6 (3-13) 7.5 (5.5-14) 0.546
24-hour NIHSS score, median (IRQ) 1 (0-4) 3 (1-6) <0.001
24-hour NIHSS score for IVT patients, median (IRQ) 3 (1-8) 2 (1-6) 0.804
IV antihypertensive use in the ED, frequency (%) 76 (10%) 18 (12%) 0.554
Intubation in the ED 21 (3%) 1 (1%) 0.235
IV thrombolysis utilization rate, frequency (%) 111 (13%) 12 (7%) 0.042
IV thrombolysis utilization rate in patients presenting within 3.5 hours, frequency (%) 102 (42%) 8 (32%) 0.433
IV thrombolysis administered at a different facility before transfer, frequency (%) 25 (5%) 3 (4%) 0.784
Mechanical thrombectomy utilization rate, frequency (%) 42 (5%) 5 (3%) 0.36
Length of stay in hours, median (IQR) 66.3 (41.7-112.6) 64 (45.1-113) 0.716
In-hospital mortality, frequency (%) 38 (5%) 1 (1%) 0.029
Discharge destination, frequency (%) 0.071
● Home ● 459 (58%) ● 113 (69%)
● Rehab/nursing home ● 242 (30%) ● 35 (21%)
● Acute care hospital ● 55 (7%) ● 12 (7%)
● Hospice ● 28 (4%) ● 4 (2%)
● Against medical advice ● 10 (1%) ● 0
Ambulatory status at discharge, frequency (%) 0.97
● Independent ● 440 (61%) ● 93 (62%)
● With assist ● 250 (35%) ● 51 (34%)
● Unable ● 31 (4%) ● 6 (4%)
STK1: VTE prophylaxis 95% 94% 0.727
STK2: discharge on antithrombotic therapy 100% 100% 1
STK3: anticoagulation therapy for atrial fibrillation/flutter 99% 100% 1
STK4: thrombolytic therapy 92% 100% 1
STK5: antithrombotic therapy by end of hospital day 2 99% 98% 0.348
STK6: discharged on statin medication 99% 100% 1
STK8: stroke education 89% 91% 0.797
STK10: rehabilitation assessment 100% 100% 1
IQR: interquartile range; HDL: high density lipoprotein; LDL: low density lipoprotein; EMS: emergency medical services; ED: emergency department; CT: computed tomography; SBP: systolic blood pressure; DBP: diastolic blood pressure; NIHSS: National Institutes of Health Stroke Scale; IV: intravenous; VTE: venous thromboembolism; STK: The Joint Commission (TJC) stroke quality metrics (note that STK7 and STK9 have been retired by TJC)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2024 MDPI (Basel, Switzerland) unless otherwise stated